US2005096388A1PendingUtilityA1

Compositions and methods for treating or preventing diseases of body passageways

62
Assignee: UNIV BRITISH COLUMBIAPriority: May 24, 1996Filed: Oct 21, 2004Published: May 5, 2005
Est. expiryMay 24, 2016(expired)· nominal 20-yr term from priority
Inventors:William L. HunterLindsay Machan
A61P 35/00A61P 31/04A61P 9/10A61P 31/06A61P 9/00A61P 43/00A61P 27/02A61P 1/04A61K 31/00A61K 31/28A61P 1/00A61K 9/0024A61K 9/1652A61P 11/00A61K 9/167A61P 15/00A61K 9/5138A61K 9/1647A61K 9/5192A61K 9/12A61K 31/337A61P 11/08A61K 9/1635A61P 13/02A61K 9/5031A61K 9/1075A61P 13/08A61K 31/335A61K 9/5153A61K 47/34A61P 13/00A61K 9/70A61K 9/7007A61K 9/10A61K 9/5146A61K 33/24
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides methods for treating or preventing diseases associated with body passageways, comprising the step of delivering to an external portion of the body passageway a therapeutic agent. Representative examples of therapeutic agents include anti-angiogenic factors, anti-proliferative agents, anti-inflammatory agents, and antibiotics.

Claims

exact text as granted — not AI-modified
1 . A method for treating or preventing an inflammatory disease associated with narrowing or obstruction of a body passageway, comprising delivering to an external portion of the body passageway of a patient in need thereof a therapeutically effective amount of an anti-angiogenic factor or a composition comprising an anti-angiogenic factor, such that the inflammatory disease is treated.  
     
     
         2 . The method of  claim 1  wherein the disease is a gastrointestinal tract disease.  
     
     
         3 . The method of  claim 2  wherein the gastrointestinal tract disease is selected from the group consisting of pancreatitis, Crohn's Disease, Ulcerative Colitis, Ulcerative Proctitis, and Primary Sclerosing Cholangitis.  
     
     
         4 . The method of  claim 2  wherein the gastrointestinal tract disease is a benign stricture.  
     
     
         5 . The method of  claim 4  wherein the benign stricture is selected from the group consisting of bile duct, esophagus, duodenum, small bowel and colon strictures.  
     
     
         6 . The method of  claim 1  wherein the inflammatory disease is vasculitis.  
     
     
         7 . The method of  claim 1  wherein the inflammatory disease is a respiratory tract disease.  
     
     
         8 . The method of  claim 7  wherein the respiratory tract disease is asthma, hypersensitivity pneumonitis, asbestosis, silicosis, chronic bronchitis, or chronic obstructive airway disease.  
     
     
         9 . The method of  claim 1  wherein the inflammatory disease is a nasolacrimal duct disease or eustachean tube disease.  
     
     
         10 . The method of  claim 1  wherein the body passageway is selected from the group consisting of lacrimal ducts, trachea, bronchi, bronchiole, nasal airways, sinus passages, eustachian tubes, and external auditory canal.  
     
     
         11 . The method of  claim 1  wherein the body passageway is selected from the group consisting of an esophagus, a stomach, a duodenum, a small intestine, a large intestine, biliary tracts, a ureter, a bladder, and a urethra.  
     
     
         12 . The method of  claim 1  wherein the anti-angiogenic factor is a compound which disrupts microtubule function.  
     
     
         13 . The method of  claim 12  wherein the compound is paclitaxel or a derivative or analogue thereof.  
     
     
         14 . The method of  claim 13  wherein the compound is paclitaxel.  
     
     
         15 . The method of  claim 13  wherein the compound is a derivative or analogue of paclitaxel.  
     
     
         16 . The method of  claim 1  wherein the anti-angiogenic factor is mitoxantrone.  
     
     
         17 . The method of  claim 1  wherein the anti-angiogenic factor is a metalloproteinase inhibitor.  
     
     
         18 . The method of  claim 1  wherein the anti-angiogenic factor is angiostatin.  
     
     
         19 . The method of  claim 1  wherein the anti-angiogenic factor is an anthracycline.  
     
     
         20 . The method of  claim 1  wherein the composition is biodegradable.  
     
     
         21 . The method of  claim 1  wherein the composition is non-biodegradable.  
     
     
         22 . The method of  claim 1  wherein the composition further comprises a polymer.  
     
     
         23 . The method of  claim 22  wherein the polymer is biodegradable.  
     
     
         24 . The method of  claim 22  wherein the polymer is non-biodegradable.  
     
     
         25 . The method of  claim 1  wherein the composition further comprises a copolymer of lactic acid and glycolic acid.  
     
     
         26 . The method of  claim 1  wherein the composition further comprises a poly(caprolactone).  
     
     
         27 . The method of  claim 1  wherein the composition further comprises a poly(lactic acid).  
     
     
         28 . The method of  claim 1  wherein the composition further comprises a. copolymer of poly(lactic acid) and poly(caprolactone).  
     
     
         29 . The method of  claim 1  wherein the composition further comprises a poly(ethylene-vinyl acetate).  
     
     
         30 . The method of  claim 1  wherein the composition further comprises a polyester.  
     
     
         31 . The method of  claim 1  wherein the composition further comprises a polyurethane.  
     
     
         32 . The method of  claim 1  wherein the composition further comprises a polyanhydride.  
     
     
         33 . The method of  claim 1  wherein the composition further comprises a gelatin.  
     
     
         34 . The method of  claim 1  wherein the composition is in the form of a paste.  
     
     
         35 . The method of  claim 1  wherein the composition is in the form of a film.  
     
     
         36 . The method of  claim 1  wherein the composition is in the form of a spray.  
     
     
         37 . The method of  claim 1  wherein the composition comprises microspheres having an average size ranging from about 0.5 μm to 200 μm.  
     
     
         38 . The method of  claim 1  wherein the anti-angiogenic factor or composition comprising the anti-angiogenic factor is administered percutaneously to the exterior surface of the body passageway.  
     
     
         39 . The method of  claim 1  wherein the anti-angiogenic factor or composition comprising the anti-angiogenic factor is applied to the adventitial surface of the body passageway.  
     
     
         40 . A method for treating or preventing an inflammatory disease associated with narrowing or obstruction of a body passageway, comprising delivering to smooth muscle cells via the adventitia of the body passageway of a patient in need thereof a therapeutically effective amount of an anti-angiogenic factor or a composition comprising an anti-angiogenic factor, such that the inflammatory disease is treated.  
     
     
         41 . The method of  claim 40  wherein the disease is a gastrointestinal tract disease.  
     
     
         42 . The method of  claim 41  wherein the gastrointestinal tract disease is selected from the group consisting of pancreatitis, Crohn's Disease, Ulcerative Colitis, Ulcerative Proctitis, and Primary Sclerosing Cholangitis.  
     
     
         43 . The method of  claim 41  wherein the gastrointestinal tract disease is a benign stricture.  
     
     
         44 . The method of  claim 43  wherein the benign stricture is selected from the group consisting of bile duct, esophagus, duodenum, small bowel and colon strictures.  
     
     
         45 . The method of  claim 40  wherein the inflammatory disease is vasculitis.  
     
     
         46 . The method of  claim 40  wherein the inflammatory disease is a respiratory tract disease.  
     
     
         47 . The method of  claim 46  wherein the respiratory tract disease is asthma, hypersensitivity pneumonitis, asbestosis, silicosis, chronic bronchitis, or chronic obstructive airway disease.  
     
     
         48 . The method of  claim 40  wherein the inflammatory disease is a nasolacrimal duct disease or eustachean tube disease.  
     
     
         49 . The method of  claim 40  wherein the body passageway is selected from the group consisting of lacrimal ducts, trachea, bronchi, bronchiole, nasal airways, sinus passages, eustachian tubes, and external auditory canal.  
     
     
         50 . The method of  claim 40  wherein the body passageway is selected from the group consisting of an esophagus, a stomach, a duodenum, a small intestine, a large intestine, biliary tracts, a ureter, a bladder, and a urethra.  
     
     
         51 . The method of  claim 40  wherein the anti-angiogenic factor is a compound which disrupts microtubule function.  
     
     
         52 . The method of  claim 51  wherein the compound is paclitaxel or a derivative or analogue thereof.  
     
     
         53 . The method of  claim 52  wherein the compound is paclitaxel.  
     
     
         54 . The method of  claim 52  wherein the compound is a derivative or analogue of paclitaxel.  
     
     
         55 . The method of  claim 40  wherein the anti-angiogenic factor is mitoxantrone.  
     
     
         56 . The method of  claim 40  wherein the anti-angiogenic factor is a metalloproteinase inhibitor.  
     
     
         57 . The method of  claim 40  wherein the anti-angiogenic factor is angiostatin.  
     
     
         58 . The method of  claim 40  wherein the anti-angiogenic factor is an anthracycline.  
     
     
         59 . The method of  claim 40  wherein the composition is biodegradable.  
     
     
         60 . The method of  claim 40  wherein the composition is non-biodegradable.  
     
     
         61 . The method of  claim 40  wherein the composition further comprises a polymer.  
     
     
         62 . The method of  claim 61  wherein the polymer is biodegradable.  
     
     
         63 . The method of  claim 61  wherein the polymer is non-biodegradable.  
     
     
         64 . The method of  claim 40  wherein the composition further comprises a copolymer of lactic acid and glycolic acid.  
     
     
         65 . The method of  claim 40  wherein the composition further comprises a poly(caprolactone).  
     
     
         66 . The method of  claim 40  wherein the composition further comprises a poly(lactic acid).  
     
     
         67 . The method of  claim 40  wherein the composition further comprises a copolymer of poly(lactic acid) and poly(caprolactone).  
     
     
         68 . The method of  claim 40  wherein the composition further comprises a poly(ethylene-vinyl acetate).  
     
     
         69 . The method of  claim 40  wherein the composition further comprises a polyester.  
     
     
         70 . The method of  claim 40  wherein the composition further comprises a polyurethane.  
     
     
         71 . The method of  claim 40  wherein the composition further comprises a polyanhydride.  
     
     
         72 . The method of  claim 40  wherein the composition further comprises a gelatin.  
     
     
         73 . The method of  claim 40  wherein the composition is in the form of a paste.  
     
     
         74 . The method of  claim 40  wherein the composition is in the form of a film.  
     
     
         75 . The method of  claim 40  wherein the composition is in the form of a spray.  
     
     
         76 . The method of  claim 40  wherein the composition comprises microspheres having an average size ranging from about 0.5 μm to 200 μm.

Join the waitlist — get patent alerts

Track US2005096388A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.